DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,738,305 | +2.4% | 23,129 | -0.9% | 0.39% | +8.0% |
| Q2 2023 | $5,603,280 | -6.7% | 23,347 | -2.0% | 0.36% | -9.3% |
| Q1 2023 | $6,006,617 | -7.7% | 23,832 | -2.8% | 0.40% | -6.6% |
| Q4 2022 | $6,509,956 | +0.6% | 24,527 | -2.1% | 0.43% | -9.3% |
| Q3 2022 | $6,472,000 | +2.0% | 25,058 | +0.1% | 0.47% | +5.1% |
| Q2 2022 | $6,347,000 | -14.5% | 25,034 | -1.1% | 0.45% | -1.8% |
| Q1 2022 | $7,427,000 | -13.1% | 25,321 | -2.5% | 0.46% | -8.8% |
| Q4 2021 | $8,544,000 | +8.3% | 25,968 | +0.2% | 0.50% | +0.6% |
| Q3 2021 | $7,887,000 | +8.1% | 25,906 | -4.8% | 0.50% | +8.0% |
| Q2 2021 | $7,299,000 | +16.1% | 27,198 | -2.6% | 0.46% | +10.6% |
| Q1 2021 | $6,286,000 | -4.1% | 27,927 | -5.4% | 0.42% | -13.0% |
| Q4 2020 | $6,557,000 | -22.6% | 29,519 | -24.9% | 0.48% | -33.7% |
| Q3 2020 | $8,469,000 | +17.5% | 39,330 | -3.5% | 0.72% | +16.3% |
| Q2 2020 | $7,210,000 | +27.5% | 40,773 | -0.2% | 0.62% | +9.0% |
| Q1 2020 | $5,653,000 | -15.3% | 40,843 | -6.1% | 0.57% | +13.8% |
| Q4 2019 | $6,678,000 | +2.8% | 43,511 | -3.3% | 0.50% | -6.2% |
| Q3 2019 | $6,499,000 | -5.1% | 44,995 | -6.0% | 0.53% | -4.8% |
| Q2 2019 | $6,845,000 | +7.4% | 47,891 | -0.8% | 0.56% | +2.9% |
| Q1 2019 | $6,376,000 | +19.5% | 48,299 | -6.7% | 0.54% | +4.8% |
| Q4 2018 | $5,337,000 | -6.8% | 51,752 | -1.8% | 0.52% | +14.3% |
| Q3 2018 | $5,726,000 | +9.8% | 52,695 | -0.3% | 0.45% | +7.3% |
| Q2 2018 | $5,215,000 | +0.5% | 52,847 | -0.3% | 0.42% | -1.6% |
| Q1 2018 | $5,188,000 | +3.0% | 52,985 | -2.3% | 0.43% | +3.9% |
| Q4 2017 | $5,035,000 | +7.6% | 54,251 | -0.6% | 0.41% | +6.4% |
| Q3 2017 | $4,680,000 | -3.7% | 54,555 | -5.3% | 0.39% | -6.9% |
| Q2 2017 | $4,859,000 | +0.2% | 57,578 | +1.5% | 0.42% | -2.6% |
| Q1 2017 | $4,851,000 | +11.9% | 56,716 | +1.9% | 0.43% | +4.1% |
| Q4 2016 | $4,335,000 | +4.7% | 55,685 | +5.4% | 0.41% | -5.7% |
| Q3 2016 | $4,140,000 | -17.2% | 52,819 | +6.7% | 0.44% | -22.7% |
| Q2 2016 | $4,999,000 | +4.6% | 49,503 | -1.8% | 0.56% | +5.8% |
| Q1 2016 | $4,781,000 | +2.4% | 50,407 | +0.2% | 0.53% | -1.5% |
| Q4 2015 | $4,670,000 | +8.8% | 50,287 | -0.2% | 0.54% | +10.2% |
| Q3 2015 | $4,293,000 | -1.6% | 50,379 | -1.2% | 0.49% | +4.0% |
| Q2 2015 | $4,363,000 | -2.3% | 50,976 | -3.1% | 0.47% | -11.6% |
| Q1 2015 | $4,464,000 | +2.5% | 52,581 | +3.4% | 0.54% | +2.3% |
| Q4 2014 | $4,356,000 | +16.8% | 50,833 | +3.6% | 0.52% | +5.9% |
| Q3 2014 | $3,729,000 | +0.6% | 49,089 | +4.3% | 0.49% | +3.3% |
| Q2 2014 | $3,705,000 | +13.1% | 47,049 | +7.7% | 0.48% | +9.4% |
| Q1 2014 | $3,275,000 | +34.2% | 43,668 | +38.2% | 0.44% | +33.2% |
| Q4 2013 | $2,441,000 | +36.8% | 31,607 | +22.8% | 0.33% | +23.8% |
| Q3 2013 | $1,784,000 | +13.6% | 25,740 | +3.7% | 0.26% | 0.0% |
| Q2 2013 | $1,571,000 | – | 24,810 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |